Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
gptkb:public_company |
| gptkbp:abbreviation |
gptkb:UCB
|
| gptkbp:CEO |
gptkb:Jean-Christophe_Tellier
|
| gptkbp:country |
gptkb:Belgium
|
| gptkbp:focus |
immunology
neurology |
| gptkbp:founded |
1928
|
| gptkbp:founder |
Emile Henri Janssen
|
| gptkbp:headquarters_location |
gptkb:Brussels
gptkb:Anderlecht |
| https://www.w3.org/2000/01/rdf-schema#label |
Union Chimique Belge
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:listedOn |
gptkb:Euronext
|
| gptkbp:notable_drug |
gptkb:Briviact
gptkb:Cimzia gptkb:Keppra gptkb:Vimpat |
| gptkbp:numberOfEmployees |
~8,600
|
| gptkbp:parentCompany |
gptkb:UCB_S.A.
|
| gptkbp:products |
gptkb:Briviact
gptkb:Cimzia gptkb:Keppra gptkb:Vimpat biopharmaceuticals |
| gptkbp:revenue |
€5.5 billion (2023)
|
| gptkbp:stockExchange |
gptkb:Euronext_Brussels
|
| gptkbp:stockSymbol |
gptkb:UCB
|
| gptkbp:website |
https://www.ucb.com/
|
| gptkbp:bfsParent |
gptkb:Hydroxyzine
|
| gptkbp:bfsLayer |
8
|